A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689Phase 3Recruiting
- Lead sponsor
- Definium Therapeutics US, Inc. (Industry)
- Enrollment
- 165 (estimated)
- Start date
- 10 May 2026
- Primary completion
- Sep 2027 (estimated)
- Study completion
- 1 Jun 2028
- Last update posted
- 23 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Triple
- Arms
- 3
Interventions
- Placebo Other
- DT120 Drug
Conditions and primary outcome
- Major Depressive Disorder
Primary outcome
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07592689.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07592689 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.